Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Next Previous
Trial Profile

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tebentafusp (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMCgp100-102
  • Sponsors Immunocore

Most Recent Events

  • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 01 Jun 2024 According to an Immunocore media release, clinical data for the treatment of patients with unresectable or metastatic uveal melanoma from this trial were presented at the 2024 ASCO (American Society for Clinical Oncology) Annual Meeting.
  • 24 Oct 2023 Results exploring effects of ImmTAC-redirected T cell activation on macrophage reprogramming using baseline and on-treatment tumor biopsies from this trial in mUM HLA-A*02:01+ patients treated with tebentafusp ; used to quantify CD163+ and CD3+ cells by immunohistochemistry, and to measure gene expression presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top